Landcent
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $1.3m | Early VC | |
N/A | $450k | Angel | |
N/A | $500k | Grant | |
$1.5m | Series A | ||
$300k | Debt | ||
$1.3m | Grant | ||
N/A | €7.8m | Grant | |
Total Funding | CAD18.6m |
Related Content
Recent News about Landcent
EditLandcent is a healthcare company focused on accelerating the fight against infectious diseases that disproportionately affect impoverished populations. The company operates in the global healthcare market, developing and delivering affordable, sustainable solutions that are safe to use at scale. Landcent's core product offerings include innovative disinfectants like Garlicin E, a non-toxic, non-corrosive, all-natural disinfectant. The company serves a diverse range of clients, including healthcare providers, non-governmental organizations (NGOs), and governments in developing countries.
Landcent's business model revolves around research and development (R&D) to create cutting-edge healthcare products. The company generates revenue through the sale of these products and potentially through partnerships and grants aimed at public health initiatives.
The leadership team includes experienced professionals like Dr. Aloys Tan and Dr. Ebere Igboko, who bring decades of expertise in healthcare and pharmaceuticals. Their combined experience spans various sectors, including social services, IT, and healthcare information systems, which helps bridge the gap between fundamental research and practical applications.
Landcent's mission is to reduce the disease burden borne by the world's poorest populations through innovative, affordable healthcare solutions.
Keywords: infectious diseases, affordable healthcare, sustainable solutions, global health, disinfectants, R&D, public health, developing countries, healthcare innovations, disease prevention.